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ABSTRACT
Although the clinical effectiveness of long-term low-
dose administration of macrolides for diffuse pan-
bronchiolitis, sinobronchial syndrome, chronic sinusitis
and otitis media with effusion has been well docu-
mented, the mechanism of action remains to be
determined. To clarify the effect of macrolides on the
initiation of immune responses, we investigated changes
in the expression levels of human leukocyte antigen
(HLA)-DR, a major histocompatibility complex class II
antigen, and of costimulatory molecules, such as CD54,
CD80 and CD86, on monocytes following administra-
tion of macrolides. The expression of HLA-DR, CD54,
CD80 and CD86 on cultured human peripheral
mononuclear cells following stimulation by interferon
(IFN)-γ and lipopolysaccharides (LPS) was analyzed
using flow cytometry in the presence and absence 
of macrolides. The macrolides tested inhibited the
expression of CD54, CD80 and CD86 on cultured
monocytes following stimulation by IFN-γ and LPS,
while the expression of HLA-DR on monocytes was not
affected. Suppression of CD80 expression was the
most significant among the costimulatory molecules
tested and occurred in a dose-dependent manner.
These results suggest that macrolides may downregulate
the expression levels of costimulatory molecules, such
as CD80, and may normalize the hyperimmune
responses that may be responsible for the chronic
intractable inflammation.
Key words: CD54, CD80, CD86, costimulatory 
molecules, human leukocyte antigen-DR, macrolides,
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INTRODUCTION
Macrolide therapy, that is, low-dose long-term adminis-
tration of 14-membered ring macrolides, has recently
been reported to be very effective in the treatment of
chronic upper respiratory infections, including diffuse pan-
bronchiolitis,1 sinobronchial syndrome,2 chronic sinusitis3,4
and otitis media with effusion.2 The mechanisms under-
lying the attenuation of chronic inflammation in the
respiratory tract remain to be determined. However, the
clinical efficacy of macrolide therapy has been suggested
to be little related to the antimicrobial effect of the
macrolide, because the treatment is also effective in
patients infected with pathogens insensitive to macro-
lides. Kudoh et al.1 have suggested that 14-membered
ring macrolides may have anti-inflammatory effects and
regulate the hyperimmune responses that lead to chronic
intractable inflammation. In accordance with this hypo-
thesis, macrolides have been reported to exhibit many
effects on immunocompetent cells, such as monocytes,
lymphocytes and neutrophils. These include effects on the
proliferation, chemotactic activities, cytokine/chemokine
production, superoxide production and expression of
adhesion molecules of these cells.
The mucosal surface of the respiratory tract is continu-
ally exposed to foreign bodies and, hence, is an important
site of immunologic activity. Immune responses against
foreign bodies are initiated by the presentation of the
antigen to T lymphocytes by antigen-presenting cells
(APC). Recent studies have shown that the proliferation 
of T cells requires the recognition of antigen/major 
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histocompatibility complex (MHC) complexes by the
T cell receptor (TCR) and, in addition, the delivery of
other non-specific costimulatory signals via molecules
expressed on the surface of the APC.5–7 The costimulatory
signals are provided efficiently by costimulatory mole-
cules, such as CD54 (intercellular adhesion molecule
(ICAM)-1), CD80 (B7–1) and CD86 (B7–2). T cell activa-
tion by the main signal in the absence of costimulatory
signals results in T cell unresponsiveness or anergy. In the
present study, to clarify the effect of macrolides on the 
initiation of immune responses, we investigated the 
effect of macrolides on the expression levels of human
leukocyte antigen (HLA)-DR, a MHC-II antigen, and co-
stimulatory molecules, such as CD54, CD80 and CD86,
on human monocytes in vitro, because a monocyte can
act as an APC.
METHODS
Materials
Erythromycin lactobionate (EM) was obtained from Abbott
Laboratories (North Chicago, IL, USA), clarithromycin
(CAM) was obtained from Taisho Pharmaceutical (Tokyo,
Japan), roxithromycin (RXM) was from Eisai Pharma-
ceutical (Tokyo, Japan) and dexamethasone (DX) was
from Banyu Pharmaceutical (Tokyo, Japan). Both EM and
DX were dissolved in distilled water and CAM and RXM
were suspended in a minimal volume of dimethyl-
sulfoxide (DMSO) and diluted with distilled water.
Escherichia coli O111:B4 lipopolysaccharide (LPS; Difco
Laboratories, Detroit, MI, USA) and interferon (IFN)-γ
(Sigma Chemical Co., St Louis, MO, USA) were sus-
pended in distilled water and sonicated. Phycoerythin
(PE)-antihuman HLA-DR, fluorescein isothiocyanate (FITC)-
antihuman CD54, FITC-antihuman CD80 and mono-
clonal antibodies IgG1 FITC/IgG1 PE/IgG1 PE-Cy5 were
purchased from Immunotek (Marseille, France). Fluorescein
isothiocyanate-antihuman CD86 and Via-Probe were
obtained from PharMingen (San Diego, CA, USA).
Normal goat serum was purchased from Cedarlane
Laboratories (Ontario, Canada).
Human mononuclear cell cultures
Heparinized peripheral blood was obtained from six
healthy adults who did not smoke or have either
acute/chronic infections or allergic diseases, including
bronchial asthma, nasal allergy and atopic dermatitis.
Blood samples were diluted twice with phosphate-
buffered saline (PBS), layered onto Ficoll–Hypaque
(Separate-L; Muto Pure Chemical, Tokyo, Japan) and
then centrifuged to isolate mononuclear cells. The mono-
nuclear cells thus obtained were washed three times 
with PBS and were suspended in RPMI 1640 medium
(Nissui, Tokyo, Japan) containing 10% fetal calf serum
(1 × 106 cells/mL). The cell suspension was preincubated
with EM, CAM, RXM (final concentrations 1 or 10 µg/mL)
or DX (final concentration 10–6 mol/L) at 37°C for 36 h in
culture wells under 5% carbon dioxide. As controls, RPMI
medium with or without the same concentration of DMSO
as that used for dissolving CAM and RXM was added to
the culture medium. After preculture, a LPS suspension
(final concentration 100 ng/mL) and IFN-γ (final concen-
tration 500 IU/mL) were added to each well. Then, EM,
CAM, RXM or DX at the same concentration was further
added to the culture medium and incubated for 12 h
under the same conditions.
Cell viability
Cell viability was measured at the end of the culture
period by the trypan blue exclusion method. Cell viabil-
ity was not altered by any concentration of the drugs
tested.
FACS analysis
Cultured mononuclear cells were preincubated with
normal goat serum for 30 min at room temperature and
then with PE-labeled antibodies against HLA-DR or
FITC-labeled antibodies against CD54, CD80 or CD86
for 30 min at 37°C. As a negative control, cells were 
also incubated with the monoclonal antibodies IgG1
FITC/IgG1 PE/IgG1 PE-Cy5. Cells were then washed
twice and fixed with formalin. Data were analyzed by
single histogram of 1 × 104 cells on a FACScan (Becton
Dickinson, Mountain View, CA, USA) gated on the mono-
cyte position in scattered dots (forward scatter (FSC), side
scatter (SSC) ). Dead cells as detected by staining with 
PE-Cy5–Via-Probe were excluded from analysis.
Statistical analysis
Statistical analysis was performed using unpaired
Student’s t-test. Two-tailed P values less than 0.05 were
considered significant.
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RESULTS
Effect of LPS and IFN-γ on the expression of
HLA-DR and costimulatory molecules on
monocytes
The expression of HLA-DR, CD54, CD80 and CD86 on
cultured human monocytes was upregulated by the addi-
tion of LPS and IFN-γ compared with expression before in
the culture medium alone (Fig. 1). Monocytes in the culture
medium containing the same amount of DMSO as that
used for dissolving CAM and RXM showed no changes in
the expression levels of any of the surface antigens.
Expression of HLA-DR on cultured monocytes
Figure 2 shows the percentage of cells in the gated area
M1 on the histogram of fluorescence intensity. None of
the agents tested had any effect on the expression of HLA-
DR on the monocytes.
Expression of CD54 on cultured monocytes
Following the addition of 10–6 mol/L DX to the culture
medium, significant downregulation of CD54 expression
on the monocytes was observed (P < 0.001). At concen-
trations of 1 and 10 µg/mL, both CAM and RXM inhibited
the expression levels of CD54 on the monocytes. In con-
trast, EM at these concentrations had little effect on CD54
expression (Fig. 3).
Expression of CD80 on cultured monocytes
With the addtion of DX, EM, CAM or RXM to the culture
medium, the expression of CD80 on monocytes following
stimulation by IFN-γ and LPS was significantly reduced com-
pared with cells cultured without any drugs. The percentage
inhibition of the expression of CD80 was the greatest with
the addition of DX and the second greatest inhibition was
observed following the addition of RXM (Fig. 4).
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Fig. 1 FACScan analysis of (a) human leukocyte antigen (HLA)-DR, (b) CD54, (c) CD80 and (d) CD86 expression on cultured
human mononuclear cells from healthy adults. Cells were gated in the monocyte position and a minimum of 1 × 104 cells in the
gated area was counted and analyzed for each profile. Thick dashed lines represent HLA-DR (a), CD54 (b), CD80 (c) or CD86 
(d) staining on monocytes with culture medium alone, while thick solid lines represent the staining on monocytes following stimula-
tion by lipopolysaccharide (100 ng/mL) and interferon-γ (500 IU/mL). Thin lines represent isotype-matched negative controls.
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Fig. 2 Effects of dexametha-
sone (DX; 10–6 mol/L) and
macrolides (1 and 10 µg/mL;
EM, erythromycin lactobionate;
CAM, clarithromycin; RXM, rox-
ithromycin) on human leukocyte
antigen (HLA)-DR expression 
on cultured mononuclear cells 
following stimulation by lipo-
polysaccharide (100 ng/mL)
and interferon-γ (500 IU/mL).
Data are the mean ± SD of 
the percentage of cells gated 
in the M1 area shown in Fig. 1a
(n = 4).
Fig. 3 Effects of dexametha-
sone (DX; 10–6 mol/L) and
macrolides (1 and 10 µg/mL;
EM, erythromycin lactobionate;
CAM, clarithromycin; RXM, 
roxithromycin) on CD54 expres-
sion on cultured mononuclear
cells following stimulation by
lipopolysaccharide (100 ng/mL)
and interferon-γ (500 IU/mL).
Data are the mean ± SD of the
percentage of cells gated in 
the M2 area shown in Fig. 1b
(n = 4). *P < 0.05, **P < 0.01
and ***P < 0.001 compared
with values in cultures without
DX or macrolides ().
Fig. 4 Effects of dexametha-
sone (DX; 10–6 mol/L) and
macrolides (1 and 10 µg/mL;
EM, erythromycin lactobionate;
CAM, clarithromycin; RXM, 
roxithromycin) on CD80 expres-
sion on cultured mononuclear
cells following stimulation by
lipopolysaccharide (100 ng/mL)
and interferon-γ (500 IU/mL).
Data are the mean ± SD of the
percentage of cells gated in the
M2 area shown in Fig. 1c
(n = 4). *P < 0.05, **P < 0.01
and ***P < 0.001 compared
with values in cultures without
DX or macrolides ().
Expression of CD86 on cultured monocytes
Figure 5 shows the percentage of cells occupying the M2
area of the histogram in the fluorescence intensity.
Although, DX failed to affect any significant reduction of
the M2%, the peak of the histogram of fluorescence
intensity was markedly shifted to the left, implying down-
regulation of the expression of CD86 by DX. Both EM and
CAM also showed an inhibitory effect on CD86 expres-
sion at high concentrations. At concentrations of both 
1 and 10 µg/mL, RXM exhibited a significant down-
regulatory effect on CD86 expression on monocytes.
DISCUSSION
Fourteen-membered ring macrolides, such as EM, RXM
and CAM have been reported to be very effective in the
treatment of chronic sinusitis and low-dose long-term
administration of macrolides (macrolide therapy) is now
the therapy of first choice for the treatment of chronic
sinusitis in Japan. The effectiveness of macrolides in 
the treatment of chronic sinusitis may not be related to 
their antimicrobial actions but, rather, to their anti-
inflammatory or immunoregulatory actions.1 Recent
studies have demonstrated that macrolides exhibit
various biologic and immunologic effects on immuno-
competent cells, fibroblasts, respiratory epithelial and
secretory cells and endothelial cells. These include: 
(i) inhibition of proliferation and differentiation;8,9
(ii) stimulation or inhibition of migration, chemotactic
activities and superoxide production;10–12 (iii) inhibition
of cytokine or chemokine production;13–16 (iv) effects on
ion-transport and Cl secretion;17,18 (v) suppression of
mucus secretion;19,20 and (vi) acceleration of apotosis.21
However, there have been few reports concerning the
effects of macrolides on the expression of surface anti-
gens on immunocompetent cells.
One of the most critical events in the initiation of the
immune response is the activation of T helper (Th) cells by
the APC. The activated Th cells produce cytokines and
express receptors for these cytokines, thereby further 
promoting Th cell proliferation. In fact, various kinds of
Th cell-derived cytokines have been detected in speci-
mens of nasal and paranasal mucosa, nasal polyps and
nasal secretion in rhinitis and sinusitis,22 indicating that 
T cells are activated in the inflammatory conditions in 
the respiratory tract. The expression of MHC class II 
molecules is primarily limited to professional APC, such
as macrophages, dendritic cells and B cells. The pres-
ence of MHC class II antigen, in the absence of costi-
mulatory signals, results, instead of T cell activation, in a
T cell unresponsive state termed clonal anergy. Some
examples of costimulatory molecules expressed on APC
are CD54 (ICAM-1), CD80 (B7–1), CD86 (B7–2), vas-
cular cell adhesion molecule (VCAM)-1 and CD58
(lymphocyte function-associated antigens-3; LFA-3).
We have recently demonstrated for the first time that
macrophages, one of the APC in nasal polyps and para-
nasal mucosa, expressed both a MHC-II (HLA-DR) and
costimulatory molecules (CD54 and CD80), using an
immunohistochemical double-staining technique.23 We
have also reported that following macrolide therapy in
patients, the number of CD4+ cells in the nasal polyps
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Fig. 5 Effects of dexametha-
sone (DX; 10–6 mol/L) and
macrolides (1 and 10 µg/mL;
EM, erythromycin lactobionate;
CAM, clarithromycin; RXM, 
roxithromycin) on CD86 expres-
sion on cultured mononuclear
cells following stimulation by
lipopolysaccharide (100 ng/mL)
and interferon-γ (500 IU/mL).
Data are the mean ± SD of the
percentage of cells gated in the
M2 area shown in Fig. 1d
(n = 4). *P < 0.05, **P < 0.01
and ***P < 0.001 compared
with values in cultures with-
out DX or macrolides ().
†Downregulation.
was decreased compared with the number in patients
who had not received macrolide therapy. However, no
difference in the number of HLA-DR-positive cells was
observed between the two groups.24 These results suggest
that macrolides may modulate the APC–T cell inter-
action. Therefore, we investigated the expression levels of
HLA-DR and those of costimulatory molecules, such as
CD54, CD80 and CD86, on monocytes, one of the APC,
in vitro. Monocytes were stimulated by LPS and IFN-γ in
the present study, because it has been shown that IFN-γ
enhances MHC class II antigen expression on human
monocytes in vitro25 and that IFN-γ induces the expres-
sion of costimulatory molecules, such as CD80 and
CD86, on synovial dendritic cells in vitro.26 In addition, a
significant level of IFN-γ can be detected in inflamed
nasal mucosa and nasal polyps, and IFN-γ may play an
important role in acute or persistent inflammation in the
respiratory tract.22
The results of our current study indicate that the expres-
sion of HLA-DR on monocytes following stimulation by
IFN-γ and LPS was not altered by the addition of either DX
or macrolides to the culture medium. Because HLA-DR is
one of the MHC class II antigens and is of importance in
the induction of the T cell immune response against
foreign bodies, it seems reasonable to assume for the
human immune system that the expression of HLA-DR is
not affected by drugs that are commonly used in medical
field.
It is generally accepted that in inflammatory condi-
tions the expression of adhesion molecules, such as
CD54, VCAM-1 and E-selectin, on endothelial cells is
increased to promote recruitment of leukocytes. In
regard to the effect of macrolides on the expression of
adhesion molecules, in vitro and in vivo studies have
shown that the expression of ICAM-1 and E-selectin on
endothelial cells or neutrophils is suppressed by the
administration of macrolides.27,28 In APC, CD54 and
VCAM-1 have been reported to act as costimulators that
activate resting T cells in the early stages of the immune
response.29,30 The present study also demonstrated that
the expression of CD54 on monocytes, upregulated fol-
lowing stimulation by LPS and IFN-γ, was reduced not
only with the addition of DX but also following the addi-
tion of CAM and RXM. However, the effect of macrolides
on the expression of CD54 was very mild compared with
that of DX.
CD80 and CD86 are costimulatory molecules that
bind to a cell surface-differentiation antigen of T cells,
namely CD28. CD80 and CD86 also bind to another
T cell-differentiation antigen, cytotoxic T lymphocyte-
associated receptor (CTLA)-4, which is expressed on
activated, but not resting, T cells. Human leukocyte-DR
and CD54 are always involved at the site of mucosal
immune responses, but the subsequent immune reaction
and immune characteristics may be controlled by CD80/
CD86 expression. A recent study has demonstrated that
both CD80 and CD86 transfectants exhibit efficient cos-
timulation of T cell proliferation, cytokine production,
such as interleukin (IL)-2 and IFN-γ, and generation of
functional cytotoxic T lymphocytes (CTL). In addition, the
magnitude and kinetics of these responses was similar
between the CD80 and CD86 transfectants.31
In the present study, the macrolides tested significantly
reduced the expression level of CD80 on monocytes in a
dose-dependent manner following stimulation by IFN-γ
and LPS. The expression of CD86 was also reduced by
the addition of macrolides to the culture medium;
however, the level of suppression of CD86 was smaller
than that of CD80. CD80 is not present on monocytes
until after their stimulation with IFN-γ,32 whereas CD86 is
constitutively expressed on resting monocytes.33 In addi-
tion, CD80 restimulates activated T cells in the late stages
of the immune response,34 whereas CD86 may be more
important in the primary interaction between monocytes
and T cells during early stages of the immune response.
Therefore, in cultured monocytes in the present study, the
difference in the pattern of suppression of costimulatory
molecule expression by DX and macrolides is reasonable.
There seem to be two possibilities concerning the mech-
anism of the inhibitory effect of macrolides on the
expression of costimulatory molecules on cultured mono-
cytes. One is the direct effect on the costimulatory
molecule protein production. The other is the indirect effect
of suppression of cytokine production by mono-nuclear
cells. Macrolides have been reported to inhibit the produc-
tion of various cytokines, such as tumour necrosis factor
(TNF)-α or IL-1, IL-4 and granulocyte–macrophage colony
stimulating factor (GM-CSF).13–16 Because TNF-α and
GM-CSF, similar to IFN-γ, have also been reported to stim-
ulate the expression of costimulatory molecules on
monocytes in vitro,27 the suppressive effect of macrolides
on such expression may be secondary to the suppression of
the production of these cytokines by macrolides.
Antigen-specific T cell activation and differentiation
sometimes induces the production of various cytokines
and the consequent activation and infiltration of inflam-
matory cells. Excessive amounts of inflammatory mediators
produced by activated cells induce tissue damage and
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lead to intractable inflammation. In the absence of co-
stimulatory molecules, T cells become anergic. In mucosal
immune response, the expression of costimulatory mole-
cules must be carefully regulated. The results of the
present study suggest that macrolides could normalize
the hyperimmune response by modulating the expression
of costimulatory molecules, such as CD80 and CD86, on
APC in chronic inflammatory conditions.
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